Treatment details | |
---|---|
Previous resection | 41 |
Localisation | |
Head | 30 (73%) |
Body | 7 (17%) |
Tail | 4 (10%) |
Resection status during primary resection | |
R0 | 25 |
R1 | 11 |
R2 | 2 |
Rx | 2 |
unknown | 1 |
Histopathological grading | |
G1 | 1 |
G2 | 25 |
G3 | 15 |
Age at time of primary resection [y] | |
Median (range) | 62 (37–75) |
Adjuvant therapy after primary resection | |
Chemotherapy | |
unknown | 35 (85%) |
6 (15%) | |
Median duration until local recurrence after primary resection [months] | |
Median (range) | 17.2 (3.1–79.7) |
Radiotherapy | |
Median dose (range) | 49.4 Gy (39.6–54) |
Concomitant Chemotherapy | |
Overall | 41 (100%) |
Gemcitabine | 37 (90%) |
5-FU/Capecitabine | 4 (10%) |
Intraoperative RT | |
Number of patients | 15 (37%) |
Median dose (range) | 15 (12–15) |
Resection state after CRT | |
total | 4 |
R0 | 3 |
R1 | 0 |
R2 | 2 |
Rx | 0 |
Negative biopsy during explorative laparoto my after CRT (number of patients) | 6 (15%) |